Repligen (RGEN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.53
- Estimate
- $0.46
- Surprise
- +14.5%
- Score at report (before → after)
- 4.3 → 4.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Repligen (RGEN) beat the $0.46 estimate with adjusted EPS of $0.53 — a large 14.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (4.3/10) to Sell at 4.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RGEN Sell at 4.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +14.5% surprise compares with a +17.0% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-source supplier (certain products)
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $175.80
- Price target
- $180.50
- Stop
- $163.49
- Upside to target
- +2.7%
- Reward-to-risk
- 0.3:1
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
RGEN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $11.16B
- P/E (fwd)
- 66.3
- 52-week range
- $100.99–$198.87
- Off 52-week high
- 11.6%
- RSI (14)
- 58
- Volume vs avg
- 1.60×
- Score today
- 4.4/10